F G Hayden

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. doi Newer influenza antivirals, biotherapeutics and combinations
    Frederick G Hayden
    Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Influenza Other Respir Viruses 7:63-75. 2013
  2. doi Experimental human influenza: observations from studies of influenza antivirals
    Frederick G Hayden
    Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA, USA
    Antivir Ther 17:133-41. 2012
  3. ncbi Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials
    Frederick G Hayden
    University of Virginia Medical School, Charlottesville, USA
    Antivir Ther 7:53-65. 2002
  4. ncbi Antivirals for influenza: historical perspectives and lessons learned
    Frederick G Hayden
    University of Virginia, School of Medicine, Department of Internal Medicine, Box 800473, Charlottesville, VA 22908, USA
    Antiviral Res 71:372-8. 2006
  5. ncbi Antiviral management of seasonal and pandemic influenza
    Frederick G Hayden
    Departments of Internal Medicine and Pathology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA
    J Infect Dis 194:S119-26. 2006
  6. ncbi Respiratory viral threats
    Frederick G Hayden
    Department of Internal Medicine, University of Virginia School of Medicine, Box 800473, Charlottesville, VA 22908, USA
    Curr Opin Infect Dis 19:169-78. 2006
  7. doi Developing new antiviral agents for influenza treatment: what does the future hold?
    Frederick Hayden
    Global Influenza Programme, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 48:S3-13. 2009
  8. pmc Perspectives on antiviral use during pandemic influenza
    F G Hayden
    Department of Internal Medicine, PO Box 800473, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Philos Trans R Soc Lond B Biol Sci 356:1877-84. 2001
  9. pmc Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers
    Frederick G Hayden
    Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 47:3907-16. 2003
  10. ncbi Pandemic influenza: is an antiviral response realistic?
    Frederick G Hayden
    University of Virginia School of Medicine, Charlottesville, VA, USA
    Pediatr Infect Dis J 23:S262-9. 2004

Detail Information

Publications80

  1. doi Newer influenza antivirals, biotherapeutics and combinations
    Frederick G Hayden
    Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Influenza Other Respir Viruses 7:63-75. 2013
    ..The development of combination interventions, immunomodulators and host-directed therapies presents unique clinical trial design and regulatory hurdles that remain to be addressed...
  2. doi Experimental human influenza: observations from studies of influenza antivirals
    Frederick G Hayden
    Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA, USA
    Antivir Ther 17:133-41. 2012
    ..The lack of availability of contemporary, safety-tested virus inoculation pools in recent years needs to be resolved in order to avoid hindering the development of new drugs and vaccines...
  3. ncbi Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials
    Frederick G Hayden
    University of Virginia Medical School, Charlottesville, USA
    Antivir Ther 7:53-65. 2002
    ..003). Pleconaril 400 mg administered three-times daily reduced the duration and severity of picornaviral VRI in adolescents and adults...
  4. ncbi Antivirals for influenza: historical perspectives and lessons learned
    Frederick G Hayden
    University of Virginia, School of Medicine, Department of Internal Medicine, Box 800473, Charlottesville, VA 22908, USA
    Antiviral Res 71:372-8. 2006
    ....
  5. ncbi Antiviral management of seasonal and pandemic influenza
    Frederick G Hayden
    Departments of Internal Medicine and Pathology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA
    J Infect Dis 194:S119-26. 2006
    ..Alternative agents and approaches, including parenteral and combination therapy, for the treatment of influenza are needed in the near and long term...
  6. ncbi Respiratory viral threats
    Frederick G Hayden
    Department of Internal Medicine, University of Virginia School of Medicine, Box 800473, Charlottesville, VA 22908, USA
    Curr Opin Infect Dis 19:169-78. 2006
    ..To assess new information from peer-reviewed publications in 2005 regarding emerging respiratory viral threats...
  7. doi Developing new antiviral agents for influenza treatment: what does the future hold?
    Frederick Hayden
    Global Influenza Programme, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 48:S3-13. 2009
    ..Among these agents are T-705, a polymerase inhibitor, and DAS181, an attachment inhibitor. Combination therapy with currently available agents is supported by data from animal models but has received limited clinical study to date...
  8. pmc Perspectives on antiviral use during pandemic influenza
    F G Hayden
    Department of Internal Medicine, PO Box 800473, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Philos Trans R Soc Lond B Biol Sci 356:1877-84. 2001
    ....
  9. pmc Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers
    Frederick G Hayden
    Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 47:3907-16. 2003
    ..Results from these studies in experimental rhinoviral infection support continued investigation of intranasal ruprintrivir in the setting of natural HRV infection...
  10. ncbi Pandemic influenza: is an antiviral response realistic?
    Frederick G Hayden
    University of Virginia School of Medicine, Charlottesville, VA, USA
    Pediatr Infect Dis J 23:S262-9. 2004
    ..Interpandemic studies demonstrate that the neuraminidase inhibitors would be effective for both prevention and treatment of influenza...
  11. ncbi Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials
    Frederick G Hayden
    Department of Internal Medicine, University of Virginia, Charlottesville, USA
    Clin Infect Dis 36:1523-32. 2003
    ..Early pleconaril treatment was well tolerated and significantly reduced the duration and severity of colds due to picornaviruses in adults...
  12. ncbi Rhinovirus and the lower respiratory tract
    Frederick G Hayden
    University of Virginia School of Medicine, Hospital Drive, Private Clinics Building, Room 6557, PO Box 800473, Charlottesville, Virginia 22908, USA
    Rev Med Virol 14:17-31. 2004
    ..Given the large unmet medical need associated with HRV infections, safe and effective antiviral agents are needed for both prevention and treatment of these infections...
  13. ncbi Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment
    F G Hayden
    University of Virginia School of Medicine, Charlottesville, USA
    JAMA 282:1240-6. 1999
    ..Influenza virus neuraminidase is thought to be essential for virus replication in humans; however, to date, available neuraminidase inhibitors are limited to zanamivir, which is topically administered...
  14. ncbi Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis
    Frederick G Hayden
    University of Virginia School of Medicine, Charlottesville, Virginia, USA
    J Infect Dis 189:440-9. 2004
    ..No oseltamivir-resistant variants were detected in treated index cases or contacts. PEP of household contacts of those with influenza reduces the secondary spread of influenza in families when the initial household case is treated...
  15. ncbi Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses
    Frederick Hayden
    Division of Infectious Disease and International Health, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA
    Antivir Ther 10:873-7. 2005
    ..The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner...
  16. ncbi Oral oseltamivir in human experimental influenza B infection
    F G Hayden
    University of Virginia School of Medicine, Department of Internal Medicine, Charlottesville, USA
    Antivir Ther 5:205-13. 2000
    ..These results indicate that oseltamivir has significant antiviral activity in experimental human influenza B virus infection when used for prophylaxis or early treatment...
  17. ncbi Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention
    F G Hayden
    Department of Internal Medicine, University of Virginia School of Medicine, Box 800473, Charlottesville, VA 22908, USA
    Vaccine 19:S66-70. 2000
    ..Depending on the virus, early antiviral therapy has the potential to impact the risk of otitis media following respiratory tract infections...
  18. pmc Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
    L V Gubareva
    Division of Epidemiology and Virology, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 45:3403-8. 2001
    ..We conclude that RWJ-270201 is a potent inhibitor of NAs of wild-type and some zanamivir-resistant or oseltamivir-resistant influenza A and B virus variants...
  19. ncbi Influenza virus neuraminidase inhibitors
    L V Gubareva
    Department of Internal Medicine, University of Virginia, School of Medicine, Charlottesville 22908, USA
    Lancet 355:827-35. 2000
    ..Because of a broader antiviral spectrum, better tolerance, and less potential for emergence of resistance than is seen with the M2 inhibitors, the neuraminidase inhibitors represent an important advance in the treatment of influenza...
  20. ncbi Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults
    L Kaiser
    University of Virginia School of Medicine, Department of Internal Medicine, Division of Epidemiology and Virology, Box 800473, Charlottesville, VA 22908, USA
    Arch Intern Med 160:3234-40. 2000
    ..Influenza infections commonly lead to respiratory tract complications that result in antibiotic treatment...
  21. ncbi Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction
    A Pitkaranta
    Department of Medicine, University of Virginia, Health Sciences Center, Charlottesville, Virginia 22908, USA
    Pediatrics 102:291-5. 1998
    ..To determine the frequencies of human rhinovirus (HRV), respiratory syncytial virus (RSV), and coronavirus (HCV) infection in children with acute otitis media (AOM)...
  22. ncbi In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses
    L Kaiser
    Department of Medicine, Division of Epidemiology and Virology, University of Virginia School of Medicine, Box 473, Charlottesville, VA 22908, USA
    Antiviral Res 47:215-20. 2000
    ..In vitro AG7088 appeared to be more potent and to have a broader antirhinoviral spectrum than pleconaril among clinical HRV isolates. The clinical relevance of these in vitro results needs to be determined in controlled clinical trials...
  23. ncbi Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
    L V Gubareva
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia, PO Box 473, Charlottesville, VA 22908, USA
    J Infect Dis 183:523-31. 2001
    ..Thus, HA affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans...
  24. pmc Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors
    Vasiliy P Mishin
    Department of Internal Medicine, School of Medicine, University of Virginia, Charlottesville, VA, USA
    J Virol 79:12416-24. 2005
    ....
  25. ncbi Antiviral resistance in influenza viruses--implications for management and pandemic response
    Frederick G Hayden
    Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, USA
    N Engl J Med 354:785-8. 2006
  26. ncbi Influenza in the acute hospital setting
    Cassandra D Salgado
    University of Virginia Health System, Charlottesville, VA 22908, USA
    Lancet Infect Dis 2:145-55. 2002
    ....
  27. ncbi Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA
    Marina S Nedyalkova
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    J Infect Dis 185:591-8. 2002
    ..Because of a lack of cell culture-based assays for susceptibility testing of human influenza viruses, detection of DeltaRNA segments should be considered an additional assay for monitoring of NA inhibitor resistance...
  28. ncbi Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment
    Luis Barroso
    Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA
    Antivir Ther 10:901-10. 2005
    ..Oseltamivir is the only oral neuraminidase inhibitor currently available; we determined the tolerability and antiviral efficacy of oral peramivir for treatment and prophylaxis of experimental human influenza A and B...
  29. ncbi Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza
    Michael G Ison
    University of Virginia, Charlottesville, VA, USA
    Antivir Ther 8:183-90. 2003
    ..Two rimantadine-resistant viruses emerged during rimantadine monotherapy; no ZNV resistance was observed. Nebulized ZNV appears to be well tolerated in this hospitalized population but further studies are needed to assess its efficacy...
  30. ncbi Therapeutic options for the management of influenza
    M G Ison
    University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville 22908, USA
    Curr Opin Pharmacol 1:482-90. 2001
    ..Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age...
  31. ncbi Recovery of drug-resistant influenza virus from immunocompromised patients: a case series
    Michael G Ison
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, 22908, USA
    J Infect Dis 193:760-4. 2006
    ..We describe a novel Asp198Asn NA mutation in an influenza B virus and its decreased susceptibility to both oseltamivir and zanamivir...
  32. ncbi Nasopharyngeal reservoir of bacterial otitis media and sinusitis pathogens in adults during wellness and viral respiratory illness
    David H Chi
    Department of Otolaryngology Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia 22906 0713, USA
    Am J Rhinol 17:209-14. 2003
    ..The carriage rate of pathogenic bacteria in the nasopharynx (NP) was determined using three separate techniques for obtaining samples...
  33. ncbi Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection
    L Kaiser
    Department of Medicine, University of Virginia School of Medicine, Charlottesville 22908, USA
    J Clin Virol 14:191-7. 1999
    ..Few data exist to assess the sensitivity of different specimen types for viral detection during the course of influenza virus infection...
  34. ncbi Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages
    E Malcolm
    Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA
    J Clin Virol 21:9-16. 2001
    ..Whether HRV directly causes viral pneumonia or predispose to pulmonary injury and/or superinfection remains uncertain...
  35. pmc Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students
    J C Turner
    Department of Student Health, University of Virginia, Charlottesville 22908, USA
    J Clin Microbiol 35:1-4. 1997
    ..equisimilis and group A beta-hemolytic streptococci were isolated. Lancefield group C beta-hemolytic streptococci appear to be associated with exudative pharyngitis in college students...
  36. ncbi Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in families
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia School of Medicine Health Sciences System, Charlottesville 22908, USA
    J Infect Dis 186:1575-81. 2002
    ..Substantial genetic conservation during virus transmission within households is indicated...
  37. ncbi Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection
    Michael G Ison
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, 22908, USA
    J Infect Dis 193:765-72. 2006
    ..This model would be useful for elucidation of the molecular mechanisms of resistance to NA inhibitors and for testing of anti-influenza therapy options that might prevent the emergence of resistant variants...
  38. ncbi Middle ear pressure in preschool age children: influence of respiratory illness, season, and picornavirus or bacteria in the nasopharynx
    Birgit Winther
    Department of Otolaryngology, Head and Neck Surgery, University of Virginia Health System, Charlottesville, VA 22908, USA
    Acta Otolaryngol 127:796-800. 2007
    ..Middle ear pressure was affected by respiratory illness and season; picornavirus (without illness) or pathogenic bacteria in the nasopharynx had no or minor effect...
  39. ncbi A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site
    Larisa V Gubareva
    Department of Internal Medicine, University of Virginia, 1300 Jefferson Park Avenue, Jordan Hall Room 2231, PO Box 800473, Charlottesville 22908, USA
    J Gen Virol 83:2683-92. 2002
    ..Hyperglycosylation of HA is common in influenza A viruses circulating in humans and has the potential to reduce virus sensitivity to NA inhibitors...
  40. ncbi Symptom profile of common colds in school-aged children
    Diane E Pappas
    Division of General Pediatrics, Department of Pediatrics, University of Virginia, Charlottesville, VA 22908, USA
    Pediatr Infect Dis J 27:8-11. 2008
    ..Subjective symptoms include nasal congestion, feverishness, headache, and sore throat. School-aged children may provide a more accurate picture of the symptom profile during colds because they can self-report...
  41. ncbi Picornavirus infections in children diagnosed by RT-PCR during longitudinal surveillance with weekly sampling: Association with symptomatic illness and effect of season
    Birgit Winther
    Department of Otolaryngology, Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia, USA
    J Med Virol 78:644-50. 2006
    ..51/child-month), episodic, and usually associated with brief illness; one fifth of infections were asymptomatic. The infection rate was highest in fall; infections in winter occurred at the same rate as in spring and summer...
  42. ncbi John F. Enders lecture 2006: antivirals for influenza
    Adrian K Ong
    Communicable Diseases Cluster, World Health Organization, Geneva, Switzerland, Geneva, CH 1211, Switzerland
    J Infect Dis 196:181-90. 2007
    ..Continued vigilance in drug resistance surveillance is imperative, as is research into the development of new agents that will provide the potential for alternative and combination antiviral therapy...
  43. ncbi Weekly point prevalence of Streptococcus pneumoniae, Hemophilus influenzae and Moraxella catarrhalis in the upper airways of normal young children: effect of respiratory illness and season
    J Owen Hendley
    Department of Pediatrics, University of Virginia Health System, Charlottesville, VA 22908, USA
    APMIS 113:213-20. 2005
    ..82, p=0.01). Detection of bacteria varied with the amount of secretion in the sample. This variation accounts for the apparent differences in bacterial carriage during illness vs. wellness and during different seasons...
  44. ncbi Experimental rhinovirus challenges in adults with mild asthma: response to infection in relation to IgE
    Juan C Zambrano
    Department of Pediatrics, University of Virginia Health System, Charlottesville, VA 22908 0386, USA
    J Allergy Clin Immunol 111:1008-16. 2003
    ..Although most children and young adults with asthma are atopic, exacerbations of asthma are frequently associated with viral respiratory tract infections, especially those caused by rhinovirus (HRV)...
  45. ncbi Effects of dietary supplementation with conjugated linoleic acid on experimental human rhinovirus infection and illness
    KRISTINE M PETERSON
    Department of Internal Medicine, University of Virginia, Charlottesville, VA, USA
    Antivir Ther 14:33-43. 2009
    ..Because studies suggest that the dietary supplement conjugated linoleic acid (CLA) has immunomodulatory activities that might benefit common colds, we performed two studies of CLA effects in experimental human rhinovirus (HRV) infection...
  46. ncbi Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay
    Larisa V Gubareva
    Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia School of Medicine, P O Box 800473, Charlottesville, VA 22908 0473, USA
    Antiviral Res 53:47-61. 2002
    ..Because variants selected in the presence of one NA inhibitor could be variably resistant to other inhibitors, all three inhibitors should be used in drug susceptibility testing...
  47. ncbi Viral respiratory infection in schoolchildren: effects on middle ear pressure
    Birgit Winther
    University of Virginia Health System, Charlottesville, Virginia 22906, USA
    Pediatrics 109:826-32. 2002
    ..To evaluate the effect of uncomplicated viral respiratory infections (colds) on middle ear pressure in healthy school-aged children...
  48. ncbi Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing
    Peter W Heymann
    Department of Pediatrics, University of Virginia Health System, Charlottesville, VA 22908 0386, USA
    J Allergy Clin Immunol 114:239-47. 2004
    ..However, information about the relationship between viral infections and atopy among children whose attacks of wheezing lead to hospitalization is unclear...
  49. ncbi Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses
    L Kaiser
    University of Virginia School of Medicine, Department of Internal Medicine, Division of Epidemiology and Virology, Charlottesville, Virginia, USA
    J Med Virol 64:262-8. 2001
    ..As in experimental influenza, symptoms and fever in natural acute influenza correlate with the release of IL-6...
  50. ncbi Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection
    Vasiliy P Mishin
    Department of Internal Medicine, University of Virginia Health Sciences System, Charlottesville, USA
    Antiviral Res 71:64-8. 2006
    ..Our results emphasize the need for careful consideration of murine strains and routes of virus challenge in the design of experiments utilizing lethal influenza virus infection...
  51. ncbi "Gesundheit!" sneezing, common colds, allergies, and Staphylococcus aureus dispersion
    Werner E Bischoff
    Department of Internal Medicine, Section on Infectious Diseases, Wake Forest University School of Medicine, Winston Salem, NC 27157 1042, USA
    J Infect Dis 194:1119-26. 2006
    ..Staphylococcus aureus is among the most important pathogens in today's hospital setting...
  52. pmc Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors
    Vasiliy P Mishin
    Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia Health Sciences Center, P O Box 800473, 1300 Jefferson Ave, Rm 2231, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 49:4515-20. 2005
    ..These studies indicate that different patterns of susceptibility and cross-resistance between NA inhibitors may prove important if antiviral resistance to zanamivir and oseltamivir were to emerge...
  53. ncbi Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia
    Michael G Ison
    Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA
    Clin Infect Dis 36:1139-43. 2003
    ..Whether the poor prognosis is due to HRV or the copathogen is not clear...
  54. ncbi Viral infections in immunocompromised patients: what's new with respiratory viruses?
    Michael G Ison
    Division of Infectious Diseases, University of Virginia, Charlottesville, Virginia 22908, USA
    Curr Opin Infect Dis 15:355-67. 2002
    ..The respiratory viruses, particularly respiratory syncytial virus, influenza, parainfluenza, adenovirus, and picornaviruses, are increasingly recognized as significant pathogens in these populations...
  55. ncbi Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection
    Birgit Winther
    University of Virginia Health System, Department of Internal Medicine, Box 800473, Charlottesville, VA 22908, USA
    Arch Otolaryngol Head Neck Surg 128:131-6. 2002
    ..Up-regulation of ICAM-1 receptor expression on nasal epithelial cells occurred within 24 hours after inoculation in experimental rhinovirus infections (prior to onset of symptoms) and declined promptly by day 5...
  56. ncbi Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model
    Vasiliy P Mishin
    Division of Infectious Diseases and International Health, Department of Internal Medicine, Health Sciences Center, University of Virginia, 1300 Jefferson Park Avenue, P O Box 800473, Charlottesville, Virginia 22908, USA
    Vaccine 23:2922-7. 2005
    ..We conclude that the NA as antigen is dispensable in the live attenuated influenza virus vaccine and that the NA-lacking mutant can be used as a virus vector...
  57. ncbi Seasonal and pandemic influenza: recommendations for preparedness in the United States
    Richard J Whitley
    Department of Pediatric, University of Alabama at Birmingham, Birmingham, AL, 35233 1711, USA
    J Infect Dis 194:S155-61. 2006
    ....
  58. ncbi Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial
    John J Treanor
    University of Rochester, Rochester, NY, USA
    JAMA 297:1577-82. 2007
    ..A high priority in vaccine research is the development of influenza vaccines that do not use embryonated eggs as the substrate for vaccine production...
  59. doi Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age
    Stan L Block
    Kentucky Pediatric and Adult Research, Bardstown, KY 40004, United States
    Vaccine 26:4940-6. 2008
    ..Live attenuated influenza vaccine (LAIV) is indicated for influenza prevention in persons 2-49 years of age. This study describes the incidence and duration of vaccine virus shedding and serum immune responses after receipt of LAIV...
  60. doi Update on avian influenza A (H5N1) virus infection in humans
    Abdel Nasser Abdel-Ghafar
    Ministry of Health and Population, Cairo
    N Engl J Med 358:261-73. 2008
  61. pmc Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use
    Arnold S Monto
    University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    Antimicrob Agents Chemother 50:2395-402. 2006
    ..The frequency of variants with decreased sensitivity to the NAIs did not increase significantly during this period, but continued surveillance is required, especially in regions with higher NAI use...
  62. pmc Kinetics of influenza A virus infection in humans
    Prasith Baccam
    Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
    J Virol 80:7590-9. 2006
    ....
  63. ncbi Multiple sclerosis attacks are associated with picornavirus infections
    John D Kriesel
    Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Mult Scler 10:145-8. 2004
    ..By contrast, only two of 12 (17%) picornavirus-negative URIs were associated with an MS attack (P = 0.01). The possible role of picornaviruses in the pathogenesis of MS deserves further study...
  64. ncbi Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom
    Beate Sander
    Institute for Medical Outcome Research GmbH, Lörrach, Germany
    Eur J Health Econ 6:244-52. 2005
    ..Oseltamivir dominates usual care from the societal perspective. Treatment with oseltamivir is a cost-effective strategy for otherwise healthy adults in the UK from both the healthcare payer and societal perspective...
  65. ncbi Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein
    Theodora M Steindl
    Department of Pharmaceutical Chemistry, Institute of Pharmacy, and Center for Molecular Biosciences Innsbruck CMBI, University of Innsbruck, Innrain 52c, A 6020 Innsbruck, Austria
    J Med Chem 48:6250-60. 2005
    ..These combined efforts led to the selection of six candidate structures, for which in vitro anti-rhinoviral activity could be shown in a biological assay...
  66. ncbi Avian influenza A (H5N1) infection in humans
    John H Beigel
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 353:1374-85. 2005
  67. pmc Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses
    Daniel C Pevear
    ViroPharma Incorporated, Exton, Pennsylvania 19341, USA
    Antimicrob Agents Chemother 49:4492-9. 2005
    ..7% of drug-treated subjects, respectively. These patients shed low levels of virus and had no unusual clinical outcomes. Nevertheless, studies on the biologic properties and transmissibility of these variant viruses are warranted...
  68. pmc Influenza, Winter Olympiad, 2002
    Adi V Gundlapalli
    University of Utah School of Medicine, Salt Lake City, Utah, USA
    Emerg Infect Dis 12:144-6. 2006
    ..Influenza A/B was diagnosed in 36 of 188 patients, including 13 athletes. Prompt management limited the spread of this outbreak...
  69. pmc Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection
    Michael P Malakhov
    NexBio, Inc, 6330 Nancy Ridge Dr, Suite 105, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 50:1470-9. 2006
    ..04 to 0.9 nM. Mouse and ferret studies confirmed significant in vivo efficacy of the sialidase fusion in both prophylactic and treatment modes...
  70. ncbi Rhinovirus and coronavirus infection-associated hospitalizations among older adults
    Ann R Falsey
    Division of Infectious Diseases and Department of Medicine, University of Rochester School of Medicine and Dentistry, and Rochester General Hospital, Rochester, New York 14621, USA
    J Infect Dis 185:1338-41. 2002
    ..These data suggest that rhinoviruses and coronaviruses may be associated with serious respiratory illnesses in frail older adults...
  71. ncbi Drug resistance and influenza pandemics
    Nikolaos I Stilianakis
    Lancet 359:1862-3. 2002
  72. ncbi Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK
    Beate Sander
    Division of Clinical Decision Making and Health Care Research, University Health Network, Toronto, Ontario, Canada
    Pharmacoeconomics 24:373-86. 2006
    ..To assess the cost effectiveness and cost utility of preventing post-exposure influenza infection using the neuraminidase inhibitor oseltamivir from a healthcare payer's perspective in the UK...
  73. ncbi Resistant influenza A viruses in children treated with oseltamivir: descriptive study
    Maki Kiso
    Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Lancet 364:759-65. 2004
    ..Our aim was to investigate oseltamivir resistance in a group of children treated for influenza...
  74. ncbi WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus
    Holger J Schunemann
    Italian National Cancer Institute Regina Elena, INFORMA Unit, Department of Epidemiology, Istituto Regina Elena, Rome, Italy
    Lancet Infect Dis 7:21-31. 2007
    ..Emergence of other novel influenza A viral subtypes with pandemic potential, or changes in the pathogenicity of H5N1 virus strains, will require an update of these guidelines and WHO will be monitoring this closely...
  75. doi The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor
    Elizabeth S Higgs
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Antiviral Res 78:64-8. 2008
    ..The establishment of a clinical research network is a vital part of preparedness and an important element during an initial response phase to a pandemic...
  76. ncbi Influenza A (H5N1): will it be the next pandemic influenza? Are we ready?
    John G Bartlett
    Ann Intern Med 143:460-2. 2005
  77. ncbi Preventing the airborne spread of Staphylococcus aureus by persons with the common cold: effect of surgical scrubs, gowns, and masks
    Werner E Bischoff
    Section on Infectious Diseases, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Infect Control Hosp Epidemiol 28:1148-54. 2007
    ..This study investigates the impact of barrier precautions on the spread of airborne S. aureus by volunteers with experimentally induced rhinovirus infection (ie, the common cold)...
  78. ncbi Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials
    M Elizabeth Halloran
    Program in Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 165:212-21. 2007
    ..Studies of influenza antivirals in transmission units would be improved if randomization schemes were used that allow estimation of the antiviral effect on infectiousness from individual studies...
  79. ncbi Clinical issues and research in respiratory failure from severe acute respiratory syndrome
    Mitchell M Levy
    Department of Medicine, Brown University Rhode Island Hospital, Providence, USA
    Am J Respir Crit Care Med 171:518-26. 2005
    ..The group recommended preparation for studies, including protocols, ethical considerations, Web-based registries, and data entry systems...